University of Chile Launches Phase 1 Clinical Trial for FMT Capsule Targeting Sarcopenia in Young Donors
Unmet Medical Needs and Market Overview of Sarcopenia
With the aging population, the demand for treatments for sarcopenia, a condition characterized by a rapid decline in muscle mass and strength due to aging, is rapidly increasing. The global sarcopenia treatment market is estimated at approximately $3.1 to $3.4 billion (USD) and is projected to grow to approximately $5.6 billion by 2035. However, there are currently no treatments approved by the FDA (U.S. Food and Drug Administration) or EMA (European Medicines Agency), and patients rely solely on non-pharmacological therapies such as exercise and protein supplements. Efforts to develop innovative new drugs to address these unmet medical needs are gradually gaining momentum.
Clinical Background Based on the Gut-Muscle Axis Theory
The ARMOR clinical trial (NCT06649981), which is now commencing, is based on the gut-muscle axis theory, which posits that gut microbial dysbiosis promotes chronic inflammation and mitochondrial dysfunction, thereby accelerating muscle loss. This study, led by researchers at the University of Chile, aims to restore the physiological regulatory system of the aging body by transplanting gut microbiota from healthy young donors. Unlike existing treatments that focus solely on increasing muscle mass, this approach aims to improve metabolic indicators and the nervous system through fecal microbiota transplantation (FMT). This is an attempt to demonstrate that this approach can be a practical solution for enhancing aging resilience.
Technical Differentiation and Clinical Design of Freeze-Dried FMT Capsules
A key technical feature of this project is the development of oral capsules containing lyophilized (freeze-dried) donor microbiota, which maximizes storage convenience. This study will be conducted at the Universidad de los Andes Clinical Trial Center in Chile in a randomized, double-blind, placebo-controlled manner in elderly patients. The study overcomes the cumbersome procedures of conventional fecal microbiota transplantation by selecting a capsule formulation that is easy to administer, thereby improving convenience. Securing this formulation will be a key competitive advantage that can improve treatment accessibility and rapidly secure market share upon entry into commercialization beyond the initial Phase 1 trial.
Funding from the Wellcome Leap Foundation and Competitive Pipeline Trends
This study is being conducted with joint research funding from the Wellcome Leap Dynamic Resilience Program and Temasek Trust, which enhances its financial credibility. In the global market, Biophytis' Sarconeos (Phase 3) and TNF Pharmaceuticals' MYMD-1 (Phase 2/3) are currently leading the way with chemical or peptide candidates. To compete with these, if FMT technology can demonstrate safety and preliminary efficacy, it will be able to pioneer a differentiated therapeutic area by leveraging the multi-target strengths of natural microbiomes. Furthermore, it will provide strong objective data for future technology transfer (out-licensing) or co-development with major pharmaceutical companies.
With the global sarcopenia treatment market reaching approximately $3.4 billion and no FDA-approved drugs available, the initiation of this Phase 1 clinical trial (ARMOR) offers the potential for a strong first-mover advantage as the first commercialization attempt based on the gut-muscle axis theory. In the short term, it will verify the safety and efficacy of the oral lyophilized capsule formulation in elderly patients, and in the medium to long term, it will be a turning point in determining the possibility of improving overall physiological function and enhancing aging resilience in sarcopenic patients. In particular, the key point to watch is whether it can secure multi-target therapeutic capabilities compared to existing synthetic drug competitors such as Biophytis' Sarconeos (Phase 3) and TNF Pharmaceuticals' MYMD-1 (Phase 2/3). With financial uncertainties in clinical trials resolved through funding from the Wellcome Leap Foundation, securing research data will serve as a catalyst for early technology export or licensing deals with global pharmaceutical companies.
Source: ClinicalTrials.gov (api_ct)